{{drugbox
| IUPAC_name = (''RS'')-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone
| image = MPHP.svg
| chirality = [[Racemic mixture]]
| width = 200px
| CAS_number = 34138-58-4
| ATC_prefix =
| ATC_suffix = 
| PubChem = 6423085
| DrugBank =
| C=17 | H=25 | N=1 | O=1
| molecular_weight = 259.385 g/mol
| smiles= c2cc(C)ccc2C(=O)C(CCCC)N1CCCC1
| ChemSpiderID = 4928584
| StdInChI = 1S/C17H25NO/c1-3-4-7-16(18-12-5-6-13-18)17(19)15-10-8-14(2)9-11-15/h8-11,16H,3-7,12-13H2,1-2H3
| StdInChIKey = YOSQVMGMENUCDX-UHFFFAOYSA-N
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = Class B
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Illegal in Sweden
| routes_of_administration = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Y8D4922F5K
}}

'''4'-Methyl-α-pyrrolidinohexiophenone''' or '''MPHP''' is a [[stimulant]] compound which has been reported as a novel [[designer drug]].<ref>{{cite journal | last1 = Springer | first1 = D | last2 = Peters | first2 = FT | last3 = Fritschi | first3 = G | last4 = Maurer | first4 = HH | title = New designer drug 4'-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry | journal = Journal of Chromatography B | volume = 789 | issue = 1 | pages = 79–91 | year = 2003 | pmid = 12726846 | doi = 10.1016/S1570-0232(03)00043-6 }}</ref><ref>{{cite journal | last1 = Peters | first1 = FT | last2 = Dragan | first2 = CA | last3 = Kauffels | first3 = A | last4 = Schwaninger | first4 = AE | last5 = Zapp | first5 = J | last6 = Bureik | first6 = M | last7 = Maurer | first7 = HH | title = Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis | journal = Journal of analytical toxicology | volume = 33 | issue = 4 | pages = 190–7 | year = 2009 | pmid = 19470220 | doi=10.1093/jat/33.4.190}}</ref><ref>{{cite journal | pmid = 21444164 | doi=10.1016/j.forsciint.2011.02.026 | volume=208 | issue=1-3 | title=Acute poisoning involving the pyrrolidinophenone-type designer drug 4'-methyl-alpha-pyrrolidinohexanophenone (MPHP) |date=May 2011 | journal=Forensic Sci. Int. | pages=e20–5}}</ref> It is closely related to [[pyrovalerone]], being simply its chain-lengthened [[Homology (chemistry)|homologue]]. In the pyrrolidinophenone series, stimulant activity is maintained so long as the positions of the [[aryl]], [[ketone]] and [[pyrrolidine|pyrrolidinyl]] groups are held constant, while the alkyl backbone can be varied anywhere between three and as many as seven carbons,<ref>{{ cite patent |country=GB |number=1149366|title=α-substituted-ketones and processes for their preparation. |status=patent}}</ref> with highest potency usually seen with the pentyl or isohexyl backbone, and a variety of substituents are tolerated on the aromatic ring.<ref>{{cite journal | last1 = Meltzer | first1 = PC | last2 = Butler | first2 = D | last3 = Deschamps | first3 = JR | last4 = Madras | first4 = BK | title = 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogs. A promising class of monoamine uptake inhibitors | journal = Journal of Medicinal Chemistry | volume = 49 | issue = 4 | pages = 1420–32 | year = 2006 | pmid = 16480278 | pmc = 2602954 | doi = 10.1021/jm050797a }}</ref>

In 2010 a group of researchers from the Institute of Forensic Medicine, University Hospital Jena, Germany concluded that MPHP can lead to serious poisoning with toxic liver damage and [[rhabdomyolysis]].<ref>{{Cite journal | last1 = Sauer | first1 = C. | last2 = Hoffmann | first2 = K. | last3 = Schimmel | first3 = U. | last4 = Peters | first4 = F. T. | title = Acute poisoning involving the pyrrolidinophenone-type designer drug 4′-methyl-alpha-pyrrolidinohexanophenone (MPHP) | doi = 10.1016/j.forsciint.2011.02.026 | journal = Forensic Science International | volume = 208 | issue = 1–3 | pages = e20–e25 | year = 2011 | pmid =  21444164| pmc = }}</ref>

==Legality==
Sweden's public health agency suggested to classify MPHP as narcotic on June 1, 2015.<ref>{{cite web | url=http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2015/juni/23-nya-amnen-kan-klassas-som-narkotika-eller-halsofarlig-vara | title=23 nya ämnen kan klassas som narkotika eller hälsofarlig vara | accessdate=29 June 2015}}</ref>

==See also==
* [[Alpha-Pyrrolidinobutiophenone|α-PBP]]
* [[Alpha-Pyrrolidinohexiophenone|α-PHP]]
* [[Alpha-Pyrrolidinopropiophenone|α-PPP]]
* [[Alpha-Pyrrolidinopentiophenone|α-PVP]]
* [[Prolintane]]

==References==
{{reflist}}

{{stimulants}}

{{DEFAULTSORT:Methyl-A-Pyrrolidinohexiophenone, 4'-}}

[[Category:Designer drugs]]
[[Category:Pyrrolidinophenones]]
[[Category:Norepinephrine-dopamine reuptake inhibitors]]
[[Category:Stimulants]]